Browse
Submit Data
Databases
API
Help

Dataset Information

29 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data from breast cancer FNA biopsies from patients

ABSTRACT: We assess if distinct biological processes might be associated with chemotherapy sensitivity in the different clinical subsets of breast cancers. We performed gene set analysis (GSA) using functionally annotated gene sets corresponding to almost all known biological processes in ER-positive/HER2negative and ER-negative/HER2-negative breast cancer, respectively. Pre-treatment FNA from primary tumors were obtained and RNA extracted and hybridized to afymetrix microarrays according to manufacturer protocol.

ORGANISM(S): Homo sapiens

SUBMITTER: IWAMOTO TAKAYUKI

PROVIDER: S-ECPF-GEOD-22093 | biostudies-other |

REPOSITORIES: biostudies-other

ACCESS DATA

Json Xml

Similar Datasets

Expression data from breast cancer FNA biopsies from patients (US samples)

Project description:This is Phase II Trial of 4courses of 5-fluorouracil, doxorubicin and cyclophosphamide follwed by 4 additional courses of weekly docetaxel and capecitabine administered as Preoperative Therapy for Patients with Locally Advanced Breast Cancer, Stages II and III by US oncology (PROTOCOL 02-103) We performed gene set analysis (GSA) using functionally annotated gene sets corresponding to almost all known biological processes in ER-positive/HER2negative and ER-negative/HER2-negative breast cancer, respectively. Pre-treatment FNA from primary tumors were obtained and RNA extracted and hybridized to afymetrix microarrays according to manufacturer protocol.

| S-ECPF-GEOD-23988 | biostudies-other

Expression data from breast cancer FNA biopsies from patients ( (USO samples)

Project description:Tumor samples were obtained from patients with stage II-III breast cancer before starting neoadjuvant chemotherapy with four cycles of 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by four cycles of docetaxel/capecitabine (TX) on US Oncology clinical trial 02-103. Most patients with HER-2-positive cancer also received trastuzumab (H). Pre-treatment FNA from primary tumors were obtained and RNA extracted and hybridized to affymetrix microarrays according to manufacturer protocol.

| S-ECPF-GEOD-42822 | biostudies-other

Expression data from Fine Needle Aspiration (FNA) biopsies from breast cancer patients

Project description:This is a stage-matched case control study. Cases with clinical diagnosis of Inflammatory Breast Cancer (IBC) were selected after reviewing all medical records of the 440 FNA samples. IBC was defined as signs of erythema and edema (peau d’orange) involving at least one third of the skin and rapid clinical presentation. Presence of tumor emboli in the dermal lymphatics of the involved skin in the pathology report was not required for inclusion as IBC. Controls were selected to match for T stage, all T4a-c tumors in the data set were included as controls. IBC breast cancer are all T4d breast cancer. We examined if gene expression differences exist between IBC and stage-matched Non-IBC stratified according to hormone receptor and HER2 status. Pre-treatment FNA from primary tumors were obtained and RNA extracted and hybridized to Affymetrix microarrays according to manufacturer protocol.

| S-ECPF-GEOD-22597 | biostudies-other

Expression data from breast cancer FNA biopsies from patients

Project description:We assess if distinct biological processes might be associated with chemotherapy sensitivity in the different clinical subsets of breast cancers. We performed gene set analysis (GSA) using functionally annotated gene sets corresponding to almost all known biological processes in ER-positive/HER2negative and ER-negative/HER2-negative breast cancer, respectively.

2010-12-31 | GSE22093 | GEO

Expression data from breast cancer FNA biopsies from patients

Project description:The behavior of breast cancers and their response to different chemotherapy treatments depend on their phenotype which is to a large extent determined by gene expression programs within the cancer cell. We used gene expression values from 30 probes on affymetrix U133A chips to calculate a score that would predict if a breast cancer is likely to achieve pathological complete response to chemotherapy consisting of T/FAC.

2010-09-15 | GSE20271 | GEO

Expression data from breast cancer FNA biopsies from patients (US samples)

2011-02-07 | GSE23988 | GEO

Expression data from breast cancer FNA biopsies from patients ( (USO samples)

2012-12-11 | GSE42822 | GEO

Expression data from breast cancer FNA biopsies from patients

2010-12-31 | E-GEOD-22093 | biostudies-arrayexpress

Expression data from Fine Needle Aspiration (FNA) biopsies from breast cancer patients

2011-07-01 | GSE22597 | GEO

Expression data from breast cancer FNA biopsies from patients (US samples)

2011-02-07 | E-GEOD-23988 | biostudies-arrayexpress